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Nucleotides are the foundation of all physiological functions.
Cancer is a kind of genetic disease and genetic changes will bring
about disturbances of nucleotide pools. Therefore, the ﬂuctuation
of nucleotide pools in cells can be considered as biomarkers to
help reveal the occurrence and development of malignancies, and
may be used to evaluate therapeutic effects in many different kind
of cancers.
The relationship between nucleotide levels and malignancies
has been veriﬁed by many studies. Growth stage changes in tumor
cells are usually accompanied by alterations of nucleotide pools;
for example, a higher rate of utilization of purine precursors has
been shown during the proliferation phase than plateau phase1.
Some studies have indicated that tumors are associated with
abnormal concentrations of normal or modiﬁed nucleosides2–4.
Moreover, the levels of nucleotide pools in tumor cells are
different from normal cells. For example, the levels of GMP and
GDP both were higher in colon cancer tissues than in normal colon
tissues, while only GMP was increased in gastric carcinoma5. The
activity of de novo synthesis of pyrimidine in MCF7 cells was 4.4
times higher than in MCF10A cells6.
Metabolomics, representing holistic thinking derived from
genomics and proteomics, is widely used in the areas of disease
diagnosis, drug development, plant metabolomics, nutritional
science and microbial metabolomics7–11. It aims at quantitative
analysis of all low molecular mass metabolites and searches for the
relationship between metabolites and changes in physiology and
pathophysiology by combining different analytical technologies
with calculation methods. The levels of nucleotides in cells will be
altered signiﬁcantly by perturbations provided by pharmaceuticals
or environmental factors12,13. Clayton et al.14 ﬁrst proposed the
concept of “pharmaco-metabonomics” in 2006: analyzing meta-
bolic proﬁles of biological samples could be a way to predict
variations of metabolic phenotypes after treatment with drugs.
Over the last several decades, many scholars have investigated the
dynamic changes in cell metabolism, cell physiological status, and
the activity of key enzymes after drug treatment. Zhang et al.15 did
research on the effect of DNA synthetase inhibitor–aphidicolin on
deoxyribonucleotide pools in human pancreatic carcinoma PANC1
cells and found that all components were increased except dUTP.
Sokoloski et al.16 found that the level of ATP decreased and UTP
increased in HL60 cell lines after inhibiting the activity of
glycinamide nucleotidyltransferase. Studies by Iwasaki et al.17
showed that ribonucleotide reductase inhibitors could prevent de
novo dCTP biosynthesis which beneﬁted are-CTP mixing into
DNA, suggesting that the antitumor activity of this category could
be reinforced by combination with nucleotide reductase inhibitors.
Studies on the effects of gemcitabine on ribonucleotides pools in
leukemia cell lines and some solid tumors showed that the level of
dNTP in cells was related to drug susceptibility, and wide
differences among NTP levels in different tumor cells reﬂecteddifferent interactions between cells and drugs18–19. Monitoring
these changes in nucleotide pools will help to predict the
therapeutic effects of antitumor drugs and reveal the targets of
drug action. Although basic analysis methods applied to cells have
long been used to aid in research on effects of drugs on
metabolites, the study of tumor cells for distinguishing different
mechanisms of drug action has not been investigated.
In our previous research, Zhang et al.20 developed a reliable,
simple and reproducible method to determine the levels of 12
nucleotides simultaneously by using an ion-pair HPLC and
analyzed the differences in nucleotide levels between normal cells
and tumor cells. The method above was further used to explore
three categories of chemotherapeutic drugs with different mecha-
nisms of action by Liu et al.21. Three classes of antitumor drugs,
including antimetabolic agents, agents directly acting on DNA and
antimitotic agents, were selected to explore their effects on
nucleotides in cells in order to ﬁnd potential biomarkers associated
with drugs. Based on the results of several analytic approaches,
GMP and ATP were chosen as the best potential biomarkers for
DNA-damaging drugs, while ATP, UDP and GMP were identiﬁed
for two other categories of drugs. However, the method we used
was not sufﬁcient to develop a model to distinguish antitumor
drugs with different mechanisms of action individually.
In this pilot study, daunorubicin (DNR), epirubicin (EPI) and
dactinomycin D (ACD), with completely different mechanisms of
action were evaluated and the best potential biomarkers were
found. Based on the earlier study, all 12 chemotherapeutic drugs
were classiﬁed into four groups by mechanism of drug action,
leading to a new and discriminatory model. Moreover, different
cell sensitivities to drugs were found which could affect the ability
to accurately recognize mechanisms of drug action.2. Methods
2.1. Chemicals and reagents
All standards (UTP-Na, ADP-Na2, AMP-Na2, ATP-Na2, CTP-
Na2, GDP-Na2, GMP-Na2, UDP-Na2, dUTP-Na3, dATP-Na3,
dCTP-Na3, dGTP-Na4) were purchased from Sigma (St. Louis,
USA). Tetrabutylammonium hydrogen sulfate (TBAHS) was
obtained from Tianjin Kermel Chemical Reagent Co., Ltd.
Methanol (HPLC grade) was obtained from Shandong Yuwang
Industrial Co., Ltd. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) and trypsin were provided by Amresco
LLC (Solon, USA). All other chemical reagents used, analytical
grade, were purchased from Tianjin Bodi Chemical Holding Co.,
Ltd. Dulbecco's modiﬁed eagle's cell culture media (DMEM),
Roswell Park Memorial Institute (RPMI) 1640 media, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and fetal
calf serum (FCS) were purchased from Gibco-BRL (Grand
Island, USA).
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Separation was performed on an Elite-L2130 HPLC system
(Hitachi Technologies, Japan) consisting of a binary solvent
delivery system and an Elite-L2400 UV detector. The UV
detection wavelength was set at 254 nm. The 12 nucleotides were
separated simultaneously by using a Synergi Hydro-C18 column
(250 mm 4.6 mm, 4.0 μm) at 25 1C. The mobile phases (A and
B) consist of phosphate, methanol and TBAHS with a constant
ﬂow of 0.8 mL/min. A gradient program was used as follows:
0–50 min, 48%–60% A; 50–68 min, 60%–100% A; 68–77 min,
100% A.2.3. Cell lines and culture conditions
All cell lines were kept in our laboratory. Human rhabdomyosar-
coma cells (A204), hepatoma cell line (HepG2), human pulmonary
carcinoma cells (A549), human ovarian carcinoma cells (SKOV3),
human breast adenocarcinoma cells (MCF7) and human breast
carcinoma cells (T47D) were cultured in DMEM medium contain-
ing 3.7 g/L NaHCO3, 10% FCS, penicillin (100 u/mL) and
streptomycin (100 μg/mL). Human ﬁbrosarcoma cells (HT1080),
human prostate carcinoma cells (PC3), human prostatic cancer
cells (DU145), human mouth epidermal carcinoma cells (KB),
Henrietta Lacks strain of cancer cells (HeLa) and human gastric
carcinoma cells (SGC7901) were maintained in RPMI-1640
medium containing 2.4 g/L HEPES, 2.0 g/L NaHCO3, 10% FCS,
penicillin (100 u/mL) and streptomycin (100 μg/mL). The 12
tumor cell lines were incubated at 37 1C with 5% CO2 in a
humidiﬁed air atmosphere. Cells were harvested in their exponen-
tial growth phase.2.4. Determination of antitumor activity
The MTT assay was used to determine the antitumor activity of
three drugs. 200 mL of cells (5 104 cells per well) were added
into 96-well plates and cultivated for 24 h. The medium was
replaced and the cells were treated with different concentrations of
antitumor drugs for 48 h. 20 mL of MTT (5 mg/mL) was added
after removing the supernatant and incubation continued for
another 4 h. To each well was added 150 mL of dimethyl sulfoxide
(DMSO) before measuring the absorbance (OD) at 492 nm using a
Thermo MK3 Reader. The half maximal inhibitory concentration
(IC50) values were determined.2.5. Cell treatment and harvest
About 1 106 cells were added into each ﬂask. After cultivation
for 24 h they were divided into a control group and a drug-treated
group. The drug-treated group was treated with antitumor drugs
according to IC50 as determined by the MTT method and the
control group was added into the same amount of medium. Cells
were harvested after 48 h.2.6. Nucleotides extraction for cells
Sample preparation was the same as the method reported
previously20. Trichloroacetic acid (TCA, 6%) was used to extract
the intracellular nucleotides on ice.2.7. Data analysis and statistics
An external standard method was used to measure the concentra-
tions of nucleotides in the tumor cells. One-way analysis of
variance (ANOVA) was calculated by SPSS 16.0 software to show
the difference of components between the control group and the
drug-treated group. The P values were recalculated by Bonferroni
correction. Principal component analysis (PCA) was performed
by SIMCA-P 11.5 demo software to understand the link
between signiﬁcant components, search for potential biomarkers,
and develop a discriminatory model. Moreover, the potential
biomarkers were validated by receiver operating characteristic
(ROC) curve.3. Results and discussion
3.1. Effect of antibiotic antitumor drugs on nucleotides
DNR, EPI and ACD are antibiotics. They express their antitumor
properties by interfering with the transcription process and
inhibiting RNA synthesis. The content of nucleotides in different
drug-treated groups varied in degree. The change trends of 12
nucleotides in cells compared with the control group were list in
Table 1 and Supporting information. The level of AMP in all cells
was increased after administration of drugs; ADP and UDP up-
regulated were observed in most cells; the main trends of UTP and
ATP were down. Based on past reports, the three drugs we chose
could disorder the function of mitochondria22–24 and induce cell
apoptosis25–27. The damage of mitochondria and apoptosis might
be the reason why the ATP level was depleted. The lower ATP
level promotes hydrolysis of ADP to supply energy for cellular
metabolism, which leads to the decreased amount of GMP.
Furthermore, the lower level of ATP also results in energy
deﬁciency when GMP is generated and induces GMP down-
regulation. Shepelevtseva et al.28 have shown that anthracycline
ring antibiotics can cause glycogen storage in cardiac muscle
tissue and decrease the content of RNA and DNA. Because
glycogen synthesis utilizes UTP to provide energy, the lower
content of UTP may be associated with glycogen synthesis. On the
other hand, the synthesis of UTP is based on CTP, so UTP down-
regulation must be accompanied with the same trend of CTP,
which is well conﬁrmed by our study. In addition, the decrease in
dGTP brings about a weaker reduction reaction from ADP to
dATP and results in a lower level of dATP.
DNR is an anthracycline antibiotic whose structure has four
combined aromatic nucleus and the shape of one molecular amino
sugar is ﬂat. As shown in Table 1, in this group, the dGMP pools
of all cells were shrunk except for two cells lines; the main trends
of dATP and dUTP were down, which suggested that the synthesis
of DNA was abnormal. Furthermore, the disorder of dNTP pools
was accompanied with other abnormal nucleotides pools that
might be connected with mechanisms of drug action. There are
several possible explanations for the mechanism of anthracyclines,
and some controversy still exists among them. Firstly, the
anthracene ring of drugs implants into DNA and its plane is
perpendicular to the axis of the helix. The amino sugar on the side
chain interacts with the sugar phosphate group of DNA by
hydrogen bonds, which makes the adduct more stable, changes
the DNA structure, and disturbs DNA replication and RNA
synthesis29. DNR inhibits the precursors mixing into DNA and
RNA30, and also inhibits DNA polymerase and RNA polymerase31.
Table 1 Change trendsa and P valuesb of 12 nucleotides in cells of each drug-treated group.
Sample DNR EPI ACD
Main trend P value Main trend P value Main trend P value
ADP ↑ (11) nnnPo0.0011 ↑ (12) nnnPo0.0011 ↑ (10) nnPo0.0055
AMP ↑ (12) nnnPo0.0011 ↑ (12) nnnPo0.0011 ↑ (12) nnnPo0.0011
ATP ↓ (12) nnnPo0.0011 ↓ (10) nnnPo0.0011 ↓ (12) nnnPo0.0011
UTP ↓ (11) nnnPo0.0011 ↓ (12) nnnPo0.0011 ↓ (12) nnnPo0.0011
CTP ↓ (12) nnPo0.0055 ↓ (10) – ↓ (12) nnnPo0.0011
dGTP ↓ (10) – ↓ (12) – ↓ (11) nnnPo0.0011
dATP ↓ (9) – ↓ (11) – ↓ (10) nnPo0.0055
GDP ↓ (8) – ↑ (7) – ↓ (9) –
GMP ↓ (9) – ↓ (8) – ↓ (9) –
UDP ↑ (7) – ↑ (9) – ↑ (8) –
dCTP ↓ (10) – ↓ (10) – ↓ (8) –
dUTP ↓ (8) – ↓ (9) – ↓ (9) –
aChanges of trend compared with the control group: ↑ up-regulated; ↓ down-regulated. The number in the bracket represents the amounts of cells
of which change of trends are in accordance with the main trend for each drug-treated group.
bP value was calculated using one-way ANOVA with Bonferroni correction (signiﬁcance at nnPo0.0055, nnnPo0.0011); –: no signiﬁcant
difference.
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DNA that keeps the reversible topoisomerase-DNA complexes in a
stable state. Thus, it leads DNA fragments to be separated32.
Thirdly, under the catalytic action of cytochrome P450 reductase,
NADPH as an electron donor regenerates DNR and produces
semiquinone free radicals, as well as active free radicals generated
under aerobic conditions, such as superoxide anion free radicals and
hydroxyl free radicals, which will cause cell membrane lipid
oxidation, cytotoxicity, damage to DNA and cardiotoxicity33.
DNR implants into a single-stranded DNA at the acting locus of
CpG ﬁrst and then ApG; DNR ﬁrst embeds into (CpG)2 base pairs
when DNR interacts with a double stranded DNA and then into
(CpA)(TpG) and (CpT)(ApG) base pairs33. As a consequence, the
unbalance of dGTP, dCTP and dATP pools may be associated with
the chelation between DNR and DNA, while the disorder of NTP
pools is connected with the inhibition of RNA synthesis. Vidal
et al.34 had studied the energy deprivation and nucleotide degrada-
tion induced by doxorubicin and DNR using isolated cardiomyo-
cytes. They found that DNR at higher concentration (150 mmol/L)
caused a fast depletion of DNA (above 40%) and an up-regulated
ADP in cytoplasm (6-fold) accompanied with released adenosine
and inosine concurrently, while a lower concentration (0.15 mmol/L)
could reduce the levels of ADP and NAD in cells. Our study is in
accordance with the result of higher concentrations of DNR.
Furthermore, glutathione (GSH) played an important role as
mediated by MRP1 in multidrug resistance (MDR) associated with
overexpression of P-glycoprotein (P-gp) and/or multidrug
resistance-associated protein (MRP1). Benderra et al.35 had inves-
tigated the regulation of glutathione modulated nuclear accumula-
tion of DNR in human MCF7 cell resistance VP-16 (MRP1
overexpression) and doxorubicin (P-gp overexpression). The
research indicated that DNR clearly accumulated in the MCF/VP
nucleus under the action of GSH-biosynthesis inhibitors. A previous
study by Cao et al.36 showed that a glucose uptake inhibitor could
increase the sensitivity of cancer cells to DNR and overcome the
drug resistance of tumor cells in hypoxia. Moreover, AKR1B10
protein participated in the metabolism of DNR and associated with
drug resistance mediated by MRP137. Consequently, drug concen-
tration, the differential expression of GSH, glucose transporter and
AKR1B10 among different tumor cells could bring about differentcell sensitivities to DNR and ﬁnally lead to different responses of
tumor cells to DNR during metabolic processes.
EPI is an isomeride of doxorubicin which has lower cardio-
toxicity. As shown in Table 1, the changes in nucleotides pools
were similar to DNR: the level of dGTP in cells was down-
regulated; the main trends of dATP and dUTP were also
decreasing; other metabolic changes in nucleotides were observed
which might be associated with the mechanism of EPI action. EPI
and DNR are anthracycline antibiotics. Their anthracene rings
implant into G and C base pairs to form a covalent bond with
DNA38, which may destroy the function of DNA template,
interfere with transcription and also prevent the synthesis of
mRNA. The interaction between EPI and DNA could induce
DNA to disintegrate and make topoisomerase II-DNA complexes
more stable.
In addition, EPI inhibits DNA helicase directly and DNA and
RNA polymerase indirectly39. In our study, a decreased amount of
dNTP was observed, which might be associated with the inhibition
of DNA synthesis, and other unbalanced nucleotides pools may
reﬂect abnormal RNA synthesis. Autophagy is a process of
decomposition depending on lysosomes in cells. Lysosomes digest
proteins or organelles and release large molecules which can be
further metabolized, while the energy generated is useful to help
cells adjust to hunger and stress, such as hypoxia, Γ-ray and
antitumor drugs. Research40 showed that EPI could induce MCF7
cell autophagy which protected MCF7 cells from EPI-induced
apoptosis. Autophagy would increase in EPI-resistance of MCF7
cell, but when autophagy was inhibited, the sensitivity of MCF7
cells would return. Cantoni et al.41 studied the effects of
doxorubicin and EPI on nucleic acid metabolism and cytotoxicity.
They found that after exposure to drug for 1 h, the extent and rate
of DNA strand breaks induced by EPI were greater than with
doxorubicin; the EPI-induced damage disappeared after removing
EPI, but was maintained in the doxorubicin group. Accordingly,
the differential of cell autophagy and the capacity of DNA repair
induced by EPI after damage might result in the interaction
between cells and drug differently, which might be the reason
that nucleotides levels in each cell line differed.
In the ACD-treated group dNTP pools were abnormal as shown
in Table 1, the content of dGTP in almost all cells was decreased
Figure 2 PCA score plot of cells in the control group and three drug-
treated groups ( Control group; DNR-treated group; ACD-
treated group; EPI-treated group). A signiﬁcant separation could be
observed between the control group and the drug-treated groups.
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These results might be associated with mechanism of drug action.
ACD is composed of a three-membered ring, a phenoxazine-3-
ketone chromophore and a two side chains of ﬁve-cyclic peptide,
action mechanism of which is to prevent DNA synthesis depend-
ing on concentrations or RNA synthesis, and inhibit RNA
synthesis. Adducts formed also break single-stranded RNA.
ACD combines with guanine and implants phenoxazine rings into
G/C base-pairs according to the result of X-ray diffraction
studies42. A cyclopeptide side chain in the minor groove of
DNA double helices reacts with bottom and side walls of minor
groove by hydrogen bonding or hydrophobic interaction to ﬁx
adducts. The peptide chain in the minor groove of DNA inhibits
RNA polymerase activity and mRNA synthesis, but can not stop
the replication of DNA. So the down regulations of dGTP and
dCTP may be the result that ACD implants into DNA, while
disturbances of other kinds of nucleotides pools also reﬂect RNA
synthesis disruption. ACD gets into cells by passive diffusion. The
uptake by cells of ACD is determined by the structure and
composition of the cytomembrane, while some substances that
change the structure of the cell membrane, such as amphotericin B,
and reinforce permeability could raise the rate of ACD uptake and
increase the lethal effect in drug-resistant cells. The differential
uptake of ACD may cause cells to react to drugs differently and
ultimately result in alterations of nucleotides pools in each cell to
varying degrees.
3.2. Statistical analysis of metabolites
Fig. 1 shows the energy charge (EC) values of tumor cells which
were calculated as follows: ([ATP]þ1/2[ADP])/ ([ATP]þ[ADP]þ
[AMP])43. The EC value, which can be a useful measure to
estimate the balance among adenine nucleotides, quantitatively
represents the energy status of high-energy phosphate bonds. As
shown in Fig. 1, the energy charge values of all tumor cells were
lower than the control group except for SGC7901 cells. Signiﬁcant
differences were observed between the drug-treated group and the
control group (Po0.01), which suggested that drugs could
interfere with energy metabolism of tumor cells and damage
mitochondria. It might be a common event by which the three
drugs of this category lead to cell death.
Signiﬁcant differences were found between the control group
and the drug-treated group by using ANOVA by SPSS 16.0. A
Bonferroni correction was used to recalculate the P value.
Po0.0055 is customarily considered as indicating statistically
signiﬁcant differences between two groups. The results (Table 1
and Supporting information) showed that levels of AMP, ADP,Figure 1 Changes in energy charge (EC) values of 12 tumor cells trea
between the drug-treated groups and the control group.UTP, ATP and CTP (Po0.0011 for the ﬁrst four and Po0.0055
for CTP) ﬂuctuated observably in the DNR-treated group, AMP,
ATP, ADP and UTP (all Po0.0011) in the EPI-treated group,
AMP, ATP, dGTP, CTP, UTP, ADP and dATP (Po0.0011 for the
ﬁrst ﬁve and Po0.0055 for the last two) in the ACD-treated
group. The contents of ATP, UTP and CTP mainly tended to
decline; moreover, the levels of AMP and ADP mostly were
elevated, which could indicate that signiﬁcant differences in
nucleotides of cells could be the potential biomarkers associated
with these three antibiotic antitumor drugs.
To investigate the overall metabolic differences, Fig. 2 repre-
sents the PCA score plot of cells in the control group and the drug-
treated groups using pattern recognition approaches by the
SIMPCA-P 11.5 Demo software. Data points marked by squares
represent the control group and the other shapes represent the
drug-treated groups. A clear and signiﬁcant separation could be
observed between the control group and the drug-treated group
which indicates that the nucleotide metabolite pattern was diffe-
rent. As shown in Fig. 2, the data points of the ACD-treated group
were rather close and the other two groups were relatively
scattered which might stem from the different structures among
three drugs. DNR and EPI belong to anthracycline-based drugs,
while ACD is a phenoxazine-based drug whose aromatic rings ﬁt
with DNA directly, which indicates that phenoxazine rings
combine with DNA more tightly. This structural difference may
lead to the differential efﬁcacy as indicated by the much smaller
IC50 values of ACD. The metabolites that contributed the most
toward classiﬁcation are shown in the loading plot (Fig. 3). Each
point represented one nucleotide on the intracellular levels and
majority of the nucleotides were clustered in the center. Outliers
including ATP, AMP, ADP and UTP contributed more to the PCAted with three drugs for 48 h. Signiﬁcant differences were observed
Figure 3 Loading plot of cells in the control group and three drug-
treated groups. Each point represented one nucleotide on the intracel-
lular levels. Tumor cells of the antibiotic antitumor drug-treated
groups were correlated with ATP, AMP, UTP and ADP.
Figure 4 ROC curve of the ability of nucleotides to discriminate
tumor cells in the control group and the drug-treated groups. UTP and
ATP were the best biomarkers for antibiotic antitumor drugs.
Figure 5 PCA score plot of cells in drug-treated groups with four
classes of mechanisms of action ( Antimetabolic agents; agents
directly acting on DNA; antimitotic agents; antibiotic agents).
Points marked by arrow were outliers which had the very largest IC50
values relative to the others of their group.
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action of antibiotic agents.
According to the results of ANOVA and PCA analysis, we
chose ATP, AMP, UTP and ADP to further assess as potential
biomarkers using ROC curve analysis by SPSS 16.0 software.
ROC curve is considered a method for diagnosing and evaluating
differences. The area under curve is used to assess the value of
test. The closer a value is to 1.0, the better a test it will be. When
the value is 0.5, it indicates that the test has no meaning. As shown
in Fig. 4, the results of ROC curve are as follows: UTP (0.988)
4ATP (0.921)4ADP (0.106)4AMP (0.035). AUCs above 0.9
mean a higher accuracy in diagnosis, therefore, UTP and ATP are
most likely to be the biomarkers for diagnosing this mechanism of
antitumor drugs.
Antibiotic anticancer drugs intercalate into G and C bases of
DNA double helices to inhibit the function of RNA polymerase.
As a result, they could interfere with the transcription process and
inhibit RNA synthesis, especially for mRNA. Our results show
that AMP, ATP, ADP and UTP might be the potential biomarkers
for this agent. To meet the huge demand for energy of tumor cell
proliferation, ATP hydrolysis will be signiﬁcant, therefore, the
intracellular ATP level will be decreased signiﬁcantly. Meanwhile,
ADP and AMP, as the products of ATP hydrolysis, will
accumulate in cells, so their levels will be up-regulated. The
variation in trends of the three nucleotides is consistent with theabnormal metabolic ways of the tumor cell, which indicates that
antibiotic drugs playing their roles of anticancer agents are not by
way of interfering with tumor cell energy metabolism. On the
other hand, the levels of ATP, CTP and UTP are all decreased.
Their shortages will inhibit RNA synthesis and interfere with the
transcription process, which is the same as the mechanism of drug
action, since they are substrates for RNA synthesis. In summary,
as the two best potential biomarkers for antibiotic anticancer drugs
according to the ROC curve, ATP levels indicates that the energy
metabolism of tumor cell is abnormal, while UTP may suggest
some biological relevance of drug action. Even though all the
changes in nucleotides cannot be explained thoroughly, the results
show that the metabolism of nucleotides is closely related to
mechanisms of drug action.3.3. Distinguishing the mechanism of antitumor drug action
So far, we have investigated the effects of 12 kinds of chemother-
apeutic drugs on nucleotides in cultured tumor cells and found
some potential biomarkers associated with drugs but failed to
develop a model to distinguish nine chemotherapeutic drugs
individually. Because similar characteristics of drugs have the
same mechanism of action, in this pilot study, 12 kind of
chemotherapeutic drugs was classiﬁed by mechanisms of drug
action into four groups: antimetabolic agents (5-ﬂuorouracil,
methotrexate and cytarabine), agents directly acting on DNA
(mitomycin C, cisplatin and etoposide), antimitotic agents (taxol,
vincristine and homoharringtonine) and antibiotic agents (DNR,
EPI and ACD). The MTT assay was used to determine the
antitumor activity of drugs. IC50 values represented the levels of
cell sensitivity to antitumor drugs and the lower value meant more
sensitivity. Four categories of drugs were investigated by PCA to
ﬁnd the link between nucleotide levels and different mechanisms
of drug action. Points represented by the same mechanism of drug
action showed a similar trend. As shown in Fig. 5, several points
marked by an arrow were far away from their groups. Interest-
ingly, these outliers had the very largest IC50 values relative to
others of their group. Maybe the cell sensitivity to antitumor drug
was too low, which resulted in the differential metabolism of
nucleotides in cells. In consequence, the different cell sensitivity to
drugs may inﬂuence the metabolism of nucleotides and the greater
the difference the greater the impact on distinguishing mechanisms
of drug action. Unfortunately, we have not found any common
statistical correlation between outliers and IC50 values. Even so,
except for the points marked by the arrow, data points grouped
Figure 6 PCA score plot of cells in antimetabolite agents and agents
directly acting on DNA ( Agents directly acting on DNA;
antimetabolic agents). Two groups could be separated from each
other well.
Distinguishing mechanisms of drug action based on metabolomics 229into three areas, of which, antimitotic agents and antibiotic agents
could be separated well while the other two groups partially
overlapped.
PCA analysis was used to ﬁnd the metabolic differences between
antimetabolic agents and agents directly acting on DNA. As shown in
Fig. 6, two groups separated from each other. Antimetabolic agents
function as antitumor drugs by combining with metabolic enzymes,
which is different from the agents that directly act on DNA, but they
all ultimately inhibit the synthesis of DNA in cells to achieve the
antitumor results, which is similar to the mechanism of agents directly
acting on DNA44–49. According to the results above, the 12 antitumor
drugs could be separated well based on their mechanisms of drug
action, which may provide a theoretical basis and a novel insight for
developing a model to predict a possible mechanism of action of an
antitumor compound in the future.4. Conclusions
In conclusion, an ion-pair RP-HPLC method was developed to
analyze 12 nucleotides in mammalian tumor cells simultaneously
for the targeted metabolomics analysis of antibiotic antitumor
drugs (DNR, EPI and ACD), in order to ﬁnd potential biomarkers.
Following HPLC and data analysis, ATP and UTP were veriﬁed
by ROC curve analysis as the most appropriate biomarkers for this
class. Moreover, four categories of drugs with different mecha-
nisms of action were analyzed by PCA to develop a discriminatory
model. Combined with IC50 values, points away from their groups
were found to have the very largest IC50 values (the lowest
sensitivity).
Metabolomics can elucidate the metabolic characteristics of
nucleotides in tumor cells treated with antitumor drugs, which
could be used to study the correlation between metabolites and
mechanisms of drug action. A more global, powerful and
metabolomics-based approach to study the correlation between
changes in metabolites and mechanisms of drug action may
become an innovative method to predict the mechanism of an
antitumor compound. Hence, the following approaches will be
pursued. Firstly, the database should be extended: only 12
nucleotides and 12 chemotherapeutic drugs were analyzed, so
more kinds of metabolites and antitumor drugs should be detected
to get a more global metabolic characteristic and develop a more
effective model. Secondly, more advanced metabolomics assay
platforms should be used, such as MS and NMR, to increase
the sensitivity and accuracy of the predictive model. Meanwhile,
the different assay platforms used together can validate and
complement each other, which can provide more information onthe connection between metabolites and antitumor drugs. Thirdly,
mechanisms of drug action should be further studied. Finding the
potential general characteristics and differences may make the
model more complete, as well as increase the ability to predict the
mechanism of an antitumor-compound action. Lastly, more
chemotherapeutic drugs of known mechanism should be used to
validate our model.
To the best of our knowledge, this is the ﬁrst development of a
discriminatory model of mechanisms of antitumor-drug action
based on metabolomics. However, to develop a more powerful
model further work is needed. The method based on metabolo-
mics, in this paper, may provide the theoretical basis of developing
a recognition model to predict a possible mechanism of an
antitumor-compound action, and also offer a novel approach to
explore the connection between metabolites in cells and mecha-
nisms of drug action.
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